Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)
Leerink Partners analyst Faisal Khurshid maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $142.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Rhythm Pharmaceuticals, and Nurix Therapeutics. According to TipRanks, Khurshid has an average return of 55.8% and a 59.02% success rate on recommended stocks.
In addition to Leerink Partners, Rhythm Pharmaceuticals also received a Buy from Morgan Stanley’s Michael Ulz in a report issued on December 12. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).
Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $51.3 million and a GAAP net loss of $52.9 million. In comparison, last year the company earned a revenue of $33.25 million and had a GAAP net loss of $43.64 million
Read More on RYTM:
Disclaimer & DisclosureReport an Issue
- Rhythm Pharmaceuticals price target raised to $157 from $141 at Goldman Sachs
- Promising Clinical Results and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $141 from $114 at Canaccord
- Rhythm Pharmaceuticals price target raised to $167 from $141 at Citizens
- Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals
